Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3.
10.4166/kjg.2016.67.3.132
- Author:
Young Kul JUNG
1
Author Information
1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea. 93cool@hanmail.net
- Publication Type:Review
- Keywords:
Antiviral agents;
Evidence-based medicine;
Genotype;
Chronic hepatitis C
- MeSH:
Antiviral Agents/*therapeutic use;
Drug Therapy, Combination;
Genotype;
Hepacivirus/*genetics/isolation & purification;
Hepatitis C/*drug therapy/virology;
Humans;
Interferon-alpha/therapeutic use;
Practice Guidelines as Topic;
Republic of Korea;
Ribavirin/therapeutic use;
Sofosbuvir/therapeutic use
- From:The Korean Journal of Gastroenterology
2016;67(3):132-136
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virological response rate of 80-90% with minimal adverse events, HCV eradication has now become a realistic goal. DAA combination treatments were approved and adapted to practice in Korea in 2015, and Korean Association for the Study of the Liver (KASL) has revised the guideline based on the systematic approach that reflects evidence-based medicine and expert opinions. In this article, new recommendations for treatment of chronic HCV genotype 2 and 3 infected patients will be introduced base on KASL practice guidelines for management of hepatitis C that has been updated in 2015.
